Deoxyribonucleic Acid (DNA) Encoding a Pan-Major Histocompatibility Complex Class II Peptide Analogue Augmented Antigen-specific Cellular Immunity and Suppressive Effects on Tumor Growth Elicited by DNA Vaccine Immunotherapy

Cancer Research

Volumn 63, Issue 22, 2003, Pages 7920-7925

  Teramoto, Koji ^a   Kontani, Keiichi ^a   Ozaki, Yoshitomo ^a   Sawai, Satoru ^a   Tezuka, Noriaki ^a   Nagata, Toshi ^b   Fujino, Shozo ^a   Itoh, Yasushi ^a   Taguchi, Osamu ^c   Koide, Yukio ^b   Asai, Tohru ^a   Ohkubo, Iwao ^a   Ogasawara, Kazumasa ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENETIC CODE; HELPER CELL; HISTOCOMPATIBILITY COMPLEX; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE, TUMOR; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; OVALBUMIN; VACCINES, DNA;

EID: 10744230048     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fayolle, C., Deriaud, E., and Leclerc, C. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J. Immunol., 147: 4069-4073, 1991.
2. Hart, M. K., Weinhold, K. J., Scearce, R. M., Washburn, E. M., Clark, C. A., Palker, T. J., and Haynes, B. F. Priming of anti-human immunodeficiency virus (HIV) CD8-cytotoxic T cell in vivo by carrier-free HIV synthetic peptides. Proc. Natl. Acad. Sci. USA, 88: 9448-9452, 1991.
3. Lasarte, J. J., Sarobe, P., Gullon, A., Prieto, J., and Borras-Cuesta, F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-I by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell. Immunol., 141: 211-218, 1992.
4. Shirai, M., Pendleton, C. D., Ahler, J., Takeshita, T., Newman, M., and Berzofsky, J. A. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol., 152: 549-556, 1994.
5. Manici, S., Sturniolo, T., Imro, M. A., Hammer, J., Sinigaglia, F., Noppen, C., Spagnoli, G., Mazzi, B., Bellone, M., Dellabona, P., and Protti, M. P. Melanoma cells present a MAGE-3 epitope to CD4 (+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med., 189: 753-756, 1999.
6. Kobayashi, H., Wood, M., Song, Y., Appella, E., and Celis, E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res., 60: 5228-5236, 2000.
7. Zarour, H. M., Maillere, B., Brusic, V., Coval, K., Williams, E., Pouvelle-Moratille, S., Castelli, F., Land, S., Bennouna, J., Logan, T., and Kirkwood, J. M. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells. Cancer Res., 62: 213-218, 2002.
8. Itoh, Y., Ogasawara, K., Takami, K., Gotohda, T., Naruse, H., Good, R. A., and Onoe, K. Determination of amino acids on agretopes of pigeon cytochrome c-related peptides specifically bound to I-A allelic products. Eur. J. Immunol., 24: 76-83, 1994.
9. b molecules. Eur. J. Immunol., 26: 1314-1321, 1996.
10. Donnelly, J. J., Ulmer, J. B., and Liu, M. A. DNA vaccine. Life Sci., 60: 163-172, 1997.
11. Maecker, H. T., Umetsu, D. T., DeKruyff, R. H., and Levy, S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J. Immunol., 161: 6532-6536, 1998.
12. Klinman, D. M., Sechler, J. M. G., Conover, J., Gu, M., and Rosenberg, A. S. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J. Immunol., 160: 2388-2392, 1998.
13. Kontani, K., Taguchi, O., Ozaki, Y., Hanaoka, J., Tezuka, N., Sawai, S., Inoue, S., Fujino, S., Maeda, T., Itoh, Y., Ogasawara, K., Sato, H., Ohkubo, I., and Kudo, T. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther., 9: 330-337, 2002.
14. Sterry, W. Vaccination therapy for malignant disease: the clinical perspective. In: P. Walden, W. Sterry, and H. Hennekes (eds.), Therapeutic Vaccination Strategies, pp. 1-6. Berlin: Springer, 2000.
15. Dermime, S., Armstrong, A., Hawkins, R. E., and Stern, P. L. Cancer vaccines and immunotherapy. Br. Med. Bull., 62: 149-162, 2002.
16. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwartz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
17. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
18. Lee, K. H., Wang, E., Nielsen, M. B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M. Increased vaccine-specific T cell frequency after peptide based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163: 6292-6300, 1999.
19. Vermorken, J. B., Claessen, A. M. E., van Tinteren, H., Gall, H. E., Ezinga, R., Meijier, S., Scheper, R. J., Meijer, C. J. L. M., Bloemena, E., Ransom, J. H., Hanna, M. G., Jr., and Pinedo, H. M. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet, 353: 345-350, 1999.
20. Chang, A. E., Redman, B. G., Whitfield, J. R., Nickoloff, B. J., Braun, T. M., Lee, P. P., Geiger, J. D., and Mule, J. J. A phase I trial of human lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res., 8: 1021-1032, 2002.
21. Ulmer, J. B., DeWitt, C. M., Chastain, M., Friedman, A., Donnelly, J. J., McClements, W. L., Caulfield, M. J., Bohannon, K. E., Volkin, D. B., and Evans, R. K. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine, 18: 18-28, 1999.
22. Ebhardt, M. B., Shive, C. L., Guardia, R., Gapin, L., Boehm, B. O., and Forsthuber, T. G. Immunological adjuvants efficiently induce antigen-specific T cell responses in old mice: implication for vaccine adjuvant development in aged individuals. Cell. Immunol., 215: 87-97, 2002.
23. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Sznol, M., Schwartz, S. L., Spiess, P. J., Wunderlich, J. R., Seipp, C. A., Einhorn, J. H., Rogers-Freezer, L., and White, D. E. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol., 163: 1690-1695, 1995.
24. Tatsumi, T., Takehara, T., Kanto, T., Miyagi, T., Kuzushita, N., Sugimoto, Y., Jinushi, M., Kasahara, A., Sasaki, Y., Hori, M., and Hayashi, N. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res., 61: 7563-7567, 2001.
25. Shimizu, K., Thomas, E. K., Giedlin, M., and Mule, J. J. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res., 61: 2618-2624, 2001.
26. Zaliauskiene, L., Kang, S., Sparks, K., Zinn, K. R., Schwiebert, L. M., Weaver, C. T., and Lollawn, J. F. Enhancement of MHC class II-restricted responses by receptor-mediated uptake of peptide antigens. J. Immunol., 169: 2337-2345, 2002.
27. Iwasaki, A., and Barber, B. H. Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor. Cancer Immunol. Immunother., 45: 273-279, 1998.
28. Chen, Y., Hu, D., Eling, D. J., Robbins, J., and Kipps, T. J. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res., 58: 1965-1971, 1998.
29. Chen, C. H., Wang, T. L., Hung, C. F., Yang, Y., Young, R. A., Pardoll, D. M., and Wu, T-C. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res., 60: 1035-1042, 2000.
30. Graham, R. A., Burchell, J. M., Beverley, P., and Taylor-Papadimitriou, J. Intramuscular immunization with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int. J. Cancer, 65: 664-670, 1996.
31. Mendirata, S. K., Thai, G., Eslahi, N. K., Thull, N. M., Mater, M., Bronte, V., and Pericle, F. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res., 61: 859-863, 2001.
32. Leitner, W. W., Ying, H., Driver, D. A., Dubensky, T. W., and Restifo, N. P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res., 60: 51-55, 2000.
33. Chan, K., Lee, D, J., Schubert, A., Tang, C. M., Crain, B., Schoenberger, S. P., and Corr, M. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA. J. Immunol., 166: 3061-3066, 2001.
34. Weiss, W. R., Ishii, K. J., Hedstrom, R. C., Sedegah, M., Ichino, M., Barnhart, K., Klinman, D. M., and Hoffman, S. L. A plasmid encoding murine granulocytemacrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol., 161: 2325-2332, 1998.
35. Chow, T. H., Chiang, B. L., Lee, Y. L., Chi, W. K., Lin, W. C., Chen, Y. T., and Tao, M. H. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol., 160: 1320-1329, 1998.
36. Maecker, H. T., Umetsu, D. T., DeKruyff, H., and Levy, S. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine, 15: 1687-1696, 1997.
37. Roman, M., Martin-Orozco, E., Googman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kombluth, R. S., Richman, D. D., Carson, D. A., and Raz, E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med., 3: 849-854, 1997.
38. Hafner, M., Zawatzky, R., Hirtreiter, C., Buurman, W. A., Echtenacher, B., Hehlgans, T., and Mannel, D. N. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res., 61: 5523-5528, 2001.
39. Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., and Schreiber, H. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA, 96: 8633-8638, 1999.
40. Beatty, G. L., and Paterson, Y. IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ. J. Immunol., 166: 2276-2282, 2001.
41. Casares, N., Lasarte, J. J., Lopez-Diaz de Cerio, A., Sarobe, P., Ruiz, M., Melero, I., Prieto, J., and Borras-Cuesta, F. Immunization with a tamor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur. J. Immunol., 31: 1780-1789, 2001.
42. Robertson, J. M., Jensen, P. E., and Evavold, B. D. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol., 164: 4706-4712, 2000.